版本:
中国

Merck & Co Inc (MRK.N)

MRK.N ( 纽约证券交易所 )

56.29USD
16 Feb 2018
涨跌 (%)

$0.30 (+0.54%)
收盘
$55.99
开盘
$55.99
当日最高
$56.98
当日最低
$55.99
成交量
4,107,505
平均成交量
3,973,811
52 周最高
$66.80
52 周最低
$53.36

Chart for

概况

Merck & Co., Inc.是一家全球保健公司。该公司通过直接销售及由合营公司销售处方药、疫苗、生物治疗药品及动物保健产品提供保健解决方案。该公司通过药品部门运营。该部门直接销售或通过合营公司销售人体健康医药及疫苗产品。人体健康医药产品包括用于治疗人体疾病的治疗剂及预防剂(通常为处方药)。该公司主要向药品批发商及... (更多)

概况

Beta: 0.79
市值(百万): $153,358.50
已发行股本(百万): 2,724.44
股息: 0.48
股息收益率 (%): 3.43

财务指标

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

UPDATE 1-Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. 全文
02/18 01:18

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Feb 17 A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc. 全文
02/17 22:41

UPDATE 1-AstraZeneca's immunotherapy drug wins key lung cancer approval

* Rival BMS, Merck, Roche drugs approved for later disease (Adds details on competition, size of market opportunity) 全文
02/17 18:07

U.S. FDA looks to pave way for earlier-stage Alzheimer's drugs

Feb 15 U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer's drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease. 全文
02/16 07:27

UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

* Merck still sees potential against lung cancer for Bavencio (Adds trial details, background on immunotherapies) 全文
02/16 00:27

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

FRANKFURT, Feb 15 Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. 全文
02/15 21:33

BRIEF-Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1

* SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1 全文
02/15 19:42

PRESS DIGEST - Wall Street Journal - Feb 15

Feb 15 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. 全文
02/15 13:37

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday. 全文
02/14 23:55

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday. 全文
02/14 20:00

竞争者

  现值 涨跌额
Johnson & Johnson (JNJ.N) $133.15 +1.92
Pfizer Inc. (PFE.N) $36.26 +0.55
AbbVie Inc (ABBV.N) $118.60 +3.70
Eli Lilly and Co (LLY.N) $78.97 +0.95
Bristol-Myers Squibb Co (BMY.N) $68.96 -0.02
Bristol-Myers Squibb Co (BMYMP.PK) $1,090.00 --

收益 vs. 预测